These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 21700623)

  • 1. Oseltamivir pharmacokinetics in morbid obesity (OPTIMO trial).
    Thorne-Humphrey LM; Goralski KB; Slayter KL; Hatchette TF; Johnston BL; McNeil SA;
    J Antimicrob Chemother; 2011 Sep; 66(9):2083-91. PubMed ID: 21700623
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of duloxetine hydrochloride enteric-coated tablets in healthy Chinese volunteers: a randomized, open-label, single- and multiple-dose study.
    Zhao RK; Cheng G; Tang J; Song J; Peng WX
    Clin Ther; 2009 May; 31(5):1022-36. PubMed ID: 19539103
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oseltamivir oral suspension and capsules are bioequivalent for the active metabolite in healthy adult volunteers.
    Lennon S; Barrett J; Kirkpatrick C; Rayner C
    Int J Clin Pharmacol Ther; 2009 Aug; 47(8):539-48. PubMed ID: 19640363
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A single-dose, three-period, six-sequence crossover study comparing the bioavailability of solution, suspension, and enteric-coated tablets of magnesium valproate in healthy Mexican volunteers under fasting conditions.
    Marcelín-Jiménez G; Angeles-Moreno AP; Contreras-Zavala L; Morales-Martínez M; Rivera-Espinosa L
    Clin Ther; 2009 Sep; 31(9):2002-11. PubMed ID: 19843490
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oseltamivir and oseltamivir carboxylate pharmacokinetics in obese adults: dose modification for weight is not necessary.
    Pai MP; Lodise TP
    Antimicrob Agents Chemother; 2011 Dec; 55(12):5640-5. PubMed ID: 21930881
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Active metabolite from Tamiflu solution is bioequivalent to that from capsule delivery in healthy volunteers: a cross-over, randomised, open-label study.
    Brewster M; Smith JR; Dutkowski R; Robson R
    Vaccine; 2006 Nov; 24(44-46):6660-3. PubMed ID: 16797800
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of oseltamivir in young and very elderly subjects.
    Abe M; Smith J; Urae A; Barrett J; Kinoshita H; Rayner CR
    Ann Pharmacother; 2006 Oct; 40(10):1724-30. PubMed ID: 16940405
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The pharmacokinetics and tolerability of oseltamivir suspension in patients on haemodialysis and continuous ambulatory peritoneal dialysis.
    Robson R; Buttimore A; Lynn K; Brewster M; Ward P
    Nephrol Dial Transplant; 2006 Sep; 21(9):2556-62. PubMed ID: 16799169
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Carboxylesterase 1 polymorphism impairs oseltamivir bioactivation in humans.
    Tarkiainen EK; Backman JT; Neuvonen M; Neuvonen PJ; Schwab M; Niemi M
    Clin Pharmacol Ther; 2012 Jul; 92(1):68-71. PubMed ID: 22588607
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of oseltamivir and oseltamivir carboxylate in critically ill patients receiving continuous venovenous hemodialysis and/or extracorporeal membrane oxygenation.
    Eyler RF; Heung M; Pleva M; Sowinski KM; Park PK; Napolitano LM; Mueller BA
    Pharmacotherapy; 2012 Dec; 32(12):1061-9. PubMed ID: 23208833
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The pharmacokinetics of daptomycin in moderately obese, morbidly obese, and matched nonobese subjects.
    Dvorchik BH; Damphousse D
    J Clin Pharmacol; 2005 Jan; 45(1):48-56. PubMed ID: 15601805
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics and pharmacodynamics of epoetin delta in two studies in healthy volunteers and two studies in patients with chronic kidney disease.
    Smith WB; Dowell JA; Pratt RD
    Clin Ther; 2007 Jul; 29(7):1368-80. PubMed ID: 17825688
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fluconazole serum concentrations and pharmacokinetics in an obese patient.
    Cohen LG; DiBiasio A; Lisco SJ; Hurford WE
    Pharmacotherapy; 1997; 17(5):1023-6. PubMed ID: 9324192
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A pharmacokinetic comparison of single doses of once-daily cyclobenzaprine extended-release 15 mg and 30 mg: a randomized, double-blind, two-period crossover study in healthy volunteers.
    Darwish M; Chang S; Hellriegel ET
    Clin Ther; 2009 Jan; 31(1):108-14. PubMed ID: 19243711
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Absence of adverse effects of oseltamivir on sleep: a double-blind, randomized study in healthy volunteers in Japan.
    Uchimura N; Kuwahara H; Kumagai Y; Mishima K; Inoue Y; Rayner CR; Toovey S; Davies BE; Hosaka Y; Abe M; Prinssen EP
    Basic Clin Pharmacol Toxicol; 2011 Oct; 109(4):309-14. PubMed ID: 21592308
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bioavailability of two oral suspension and two oral tablet formulations of acyclovir 400 mg: two single-dose, open-label, randomized, two-period crossover comparisons in healthy Mexican adult subjects.
    Palma-Aguirre JA; Absalón-Reyes JA; Novoa-Heckel G; de Lago A; Oliva I; Rodríguez Z; González-de la Parra M; Burke-Fraga V; Namur S
    Clin Ther; 2007 Jun; 29(6):1146-52. PubMed ID: 17692728
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum piperacillin/tazobactam pharmacokinetics in a morbidly obese individual.
    Newman D; Scheetz MH; Adeyemi OA; Montevecchi M; Nicolau DP; Noskin GA; Postelnick MJ
    Ann Pharmacother; 2007 Oct; 41(10):1734-9. PubMed ID: 17726066
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of orally administered oseltamivir in healthy obese and nonobese Thai subjects.
    Jittamala P; Pukrittayakamee S; Tarning J; Lindegardh N; Hanpithakpong W; Taylor WR; Lawpoolsri S; Charunwattana P; Panapipat S; White NJ; Day NP
    Antimicrob Agents Chemother; 2014; 58(3):1615-21. PubMed ID: 24366750
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic and pharmacodynamic assessments of the dipeptidyl peptidase-4 inhibitor PHX1149: double-blind, placebo-controlled, single- and multiple-dose studies in healthy subjects.
    O'Farrell AM; van Vliet A; Abou Farha K; Cherrington JM; Campbell DA; Li X; Hanway D; Li J; Guler HP
    Clin Ther; 2007 Aug; 29(8):1692-705. PubMed ID: 17919550
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bioequivalence and tolerability of two clopidogrel salt preparations, besylate and bisulfate: a randomized, open-label, crossover study in healthy Korean male subjects.
    Kim SD; Kang W; Lee HW; Park DJ; Ahn JH; Kim MJ; Kim EY; Kim SW; Nam HS; Na HJ; Yoon YR
    Clin Ther; 2009 Apr; 31(4):793-803. PubMed ID: 19446152
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.